In the present study, the treatment with peptides delayed development of nephropathy in in vivo model of diabetes, resulting in reduction of albuminuria, urinary TNF‐α and TNFR1 levels, membrane thickness, and mesangial expansion compared to diabetic control mice. This evidence concerns the gene TNFRSF1A and diabetes mellitus.